Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders

Abstract : The effector functions of T lymphocytes are responsible for most autoimmune disorders and act by directly damaging tissues or by indirectly promoting inflammation and antibody responses. Co-stimulatory and co-inhibitory T cell receptor molecules are the primary pharmacological targets that enable interference with immune-mediated diseases. Among these, selective CD28 antagonists have drawn special interest, since they tip the co-stimulation/co-inhibition balance towards efficiently inhibiting effector T cells while promoting suppression by pre-existing regulatory T-cells. After having demonstrated outstanding therapeutic efficacy in multiple models of autoimmunity, inflammation and transplantation, and safety in phase-I studies in humans, selective CD28 antagonists are currently in early clinical development for the treatment of systemic lupus erythematous and rheumatoid arthritis. Here, we review the available proof of concept studies for CD28 antagonists in autoimmunity, with a special focus on the mechanisms of action.
Document type :
Journal articles
Complete list of metadatas

Cited literature [88 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01885571
Contributor : Nicolas Degauque <>
Submitted on : Tuesday, October 2, 2018 - 9:34:47 AM
Last modification on : Friday, March 29, 2019 - 10:40:09 AM
Long-term archiving on : Thursday, January 3, 2019 - 1:17:32 PM

File

antibodies-06-00019-v2.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Bernard Vanhove, Nicolas Poirier, Fadi Fakhouri, Laetitia Laurent, Bert Hart, et al.. Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. Antibodies, MDPI, 2017, 6, pp.19. ⟨10.3390/antib6040019⟩. ⟨inserm-01885571⟩

Share

Metrics

Record views

60

Files downloads

102